PMID- 29080744
OWN - NLM
STAT- MEDLINE
DCOM- 20180105
LR  - 20180105
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 495
IP  - 1
DP  - 2018 Jan 1
TI  - Effect of dexmedetomidine on rats with convulsive status epilepticus and 
      association with activation of cholinergic anti-inflammatory pathway.
PG  - 421-426
LID - S0006-291X(17)32104-6 [pii]
LID - 10.1016/j.bbrc.2017.10.124 [doi]
AB  - Convulsive status epilepticus (CSE) is a neurological disease with contraction 
      and extension of limbs, leading to damage of hippocampus and cognition. This 
      study aimed to explore the effects of dexmedetomidine (DEX) on the cognitive 
      function and neuroinflammation in CSE rats. All rats were divided into control 
      group, CSE group and DEX group. Morris water maze test was used to measure 
      cognitive function. Acute hippocampal slices were made to detect long-term 
      potentiation (LTP). Immunohistochemistry was used to determine the expression of 
      alpha7-nicotinic acetylcholine receptor (alpha7-nAChR) and interleukin-1beta (IL-1beta). 
      Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of 
      IL-1beta, tumor necrosis factor-alpha (TNF-alpha), S-100beta and brain-derived neurotrophic 
      factor (BDNF). Our results showed that DEX improved the memory damage caused by 
      CSE. DEX reduced seizure severity and increased the amplitudes and sustainable 
      time of LTP, and also inhibited the hippocampal expression of alpha7-nAChR and IL-1beta 
      in CSE rats. DEX treatment decreased serum IL-1beta, TNF-alpha and S-100beta levels and 
      increased BDNF levels. The effects of DEX on seizure severity and LTP could be 
      simulated by nicotine or attenuated by concurrent alpha-bungarotoxin (alpha-BGT) 
      treatment. In conclusions, DEX significantly improved spatial cognitive 
      dysfunction, reduced seizure severity and increased LTP in CSE rats. Improvements 
      by DEX were closely related to enhancement of cholinergic anti-inflammatory 
      pathway.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Xu, Kai-Liang
AU  - Xu KL
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Liu, Xin-Qiu
AU  - Liu XQ
AD  - Shanghai Institute of Medical Genetics, Shanghai Children's Hospital Affiliated 
      to Shanghai Jiao-Tong University, Shanghai 200040, PR China.
FAU - Yao, Yu-Long
AU  - Yao YL
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Ye, Ming-Rong
AU  - Ye MR
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Han, Yao-Guo
AU  - Han YG
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China.
FAU - Lei, Ming
AU  - Lei M
AD  - Department of Critical Care Medicine, Seventh People's Hospital of Shanghai 
      University of TCM, Shanghai 200137, PR China. Electronic address: 
      leiming6891@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171111
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anticonvulsants)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (alpha7 Nicotinic Acetylcholine Receptor)
RN  - 67VB76HONO (Dexmedetomidine)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Anticonvulsants/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/analysis/immunology
MH  - Dexmedetomidine/*therapeutic use
MH  - Hippocampus/drug effects/immunology/pathology/physiopathology
MH  - Interleukin-1beta/analysis/immunology
MH  - Long-Term Potentiation/drug effects
MH  - Male
MH  - Memory/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Seizures/*drug therapy/immunology/pathology/physiopathology
MH  - Status Epilepticus/*drug therapy/immunology/pathology/physiopathology
MH  - Tumor Necrosis Factor-alpha/analysis/immunology
MH  - alpha7 Nicotinic Acetylcholine Receptor/analysis/immunology
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor (BDNF)
OT  - Convulsive status epilepticus (CSE)
OT  - Dexmedetomidine (DEX)
OT  - Interleukin-1 (IL-1beta)
OT  - alpha7-nicotinic acetylcholine receptor (alpha7-nAChR)
EDAT- 2017/10/31 06:00
MHDA- 2018/01/06 06:00
CRDT- 2017/10/30 06:00
PHST- 2017/10/12 00:00 [received]
PHST- 2017/10/24 00:00 [accepted]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2018/01/06 06:00 [medline]
PHST- 2017/10/30 06:00 [entrez]
AID - S0006-291X(17)32104-6 [pii]
AID - 10.1016/j.bbrc.2017.10.124 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2018 Jan 1;495(1):421-426. doi: 
      10.1016/j.bbrc.2017.10.124. Epub 2017 Nov 11.